Endonovo Therapeutics, Inc.

Efficacy Study of PEMF in Mouse Model of Myocardial Infarction

January 2018
Disclosure Statements

THE INFORMATION CONTAIN HEREIN IS CONFIDENTIAL AND IS INTENDED ONLY FOR THE USE OF THE PERSON TO WHOM IT IS TRANSMITTED BY ENDONOVO THERAPEUTICS. NEITHER THIS PRESENTATION NOR ANY PART OF IT MAY BE COPIED, DISCLOSED OR TRANSFERRED WITHOUT EXPRESS WRITTEN CONSENT OF ENDONOVO THERAPEUTICS.

FORWARD-LOOKING STATEMENTS:

All statements, trends, analysis, and other information contained in this presentation including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” and “intend” and other similar expressions of opinion, constitute forward-looking statements. These forward-looking statements are subject to business and economic risks, and Endonovo’s actual results of operations may differ materially from those contained in the forward-looking statements.

In addition, the statements contained herein reflect Endonovo’s expectations as of the date of this presentation. Endonovo anticipates that subsequent events and developments may cause Endonovo’s expectations and beliefs to change. However, while Endonovo may elect to update these forward-looking statements at some point in time, Endonovo specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as a representation of Endonovo’s views or expectations as of any date after the date of this presentation.
Experimental Protocol

- MI
- Echo
- Echo
- Echo

4 weeks

PEMF:
- 1T, once a day
- 2T, twice a day
- 3T, three times a day
- CON, placebo

2 weeks

Left ventricular pressure
Heart weight
Body weight
Histology (trichrome stain)
Effect of PEMF Treatments on Cardiac Remodeling

<table>
<thead>
<tr>
<th>Group</th>
<th>Mean HW (mg)</th>
<th>SD (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CON</td>
<td>178.5</td>
<td>23.07</td>
</tr>
<tr>
<td>1T</td>
<td>171</td>
<td>22.01</td>
</tr>
<tr>
<td>2T</td>
<td>163</td>
<td>20.41</td>
</tr>
<tr>
<td>3T</td>
<td>164.4</td>
<td>11.69</td>
</tr>
</tbody>
</table>

HW: Heart Weight, SD: Standard Deviation
Treating Infarcted Mice With PEMF Two or Three Times a Day Inhibited Cardiac Remodeling

HW/BW = Heart Weight-to-Body Weight Ratio

*: p<0.05, 2T vs. CON
#: p<0.05, 3T vs. CON
Treating Infarcted Mice With PEMF Two or Three Times a Day Increased Cardiac Contraction

*: p<0.01, 2T/3T vs. CON
#: p<0.05, 3T vs. CON

LVDP (mm Hg)

dp/dtm (mm Hg/sec)
PEMF Improved Cardiac Function in Infarcted Mice

*: p<0.01, T2/T3 vs. CON
#: p<0.05, T1 vs. CON
PEMF Two or Three Times a Day Decreased Ventricular Dilation in Infarcted Mice

*: p<0.05, 2T/3T vs. CON

LVESD: Left Ventricular End-Systolic Diameter
PEMF Improved Cardiac Repair in Infarcted Mice

IVSS: Interventricular Septal Dimension at Systole

*: p<0.05, 2T/3T vs. CON
#: p<0.05, 2T vs. CON
$: P<0.05, 1T VS. CON

[Graph showing IVSS (mm) over weeks for different conditions: CON, 1T, 2T, 3T]
PEMF Decreased Myocardial Infarct Size in Mice After Occlusion of The Left Coronary Artery

Infarct size

<table>
<thead>
<tr>
<th>CON</th>
<th>1T</th>
<th>2T</th>
<th>3T</th>
</tr>
</thead>
</table>

*: p<0.01, 2T vs. CON
#: p<0.01, 1T vs. CON
$: P<0.05, 3T VS. CON
Treating Infarcted Mice With PEMF One or Two Times a Day Inhibited Cardiac Fibrosis
Treating Infarcted Mice With PEMF One or Two Times a Day Inhibited Cardiac Fibrosis

*: p<0.05, 2T vs. CON
#: p<0.05, 1T vs. CON
$: P>0.05, 3T VS. CON
PEMF Two Times a Day Raised Blood BNP Levels in Infarcted Mice

*: p<0.05, 2T vs. CON
Summary

PEMF improved cardiac function and ventricular remodeling in mice after MI in a dose-dependent manner, possibly by increasing BNP production and inhibiting fibrosis in the heart.